Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig

Vaccine

Volumn 29, Issue 11, 2011, Pages 2071-2078

  Bernstein, David I ^a   Earwood, Julie D ^a   Bravo, Fernando J ^a   Cohen, Gary H ^b   Eisenberg, Roselyn J ^b   Clark, Jennifer R ^a   Fairman, Jeffrey ^c   Cardin, Rhonda D ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Juvaris BioTherapeutics Inc   (United States)

Author keywords

CLDC adjuvant; Genital herpes; Guinea pig; Herpes simplex; HSV glycoproteins; HSV vaccine

Indexed keywords

CATIONIC LIPOSOME DNA COMPLEX; HERPES SIMPLEX VACCINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DNA ISOLATION; DRUG EFFICACY; FEMALE; GENITAL HERPES; GUINEA PIG; HERPES SIMPLEX VIRUS 2; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; SPINAL CORD; SPINAL GANGLION; T LYMPHOCYTE; VIRUS REPLICATION; VIRUS SHEDDING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; FEMALE; GANGLIA, SPINAL; GUINEA PIGS; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 2, HUMAN; LIPOSOMES; NEUTRALIZATION TESTS; SPINAL CORD; VIRAL ENVELOPE PROTEINS; VIRUS LATENCY; VIRUS SHEDDING;

EID: 79951809023     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.005     Document Type: Article

References (43)

1. Gupta R., Warren T., Wald A. Genital herpes. Lancet 2007, 370(December (9605)):2127-2137.
2. Wald A., Corey L. How does herpes simplex virus type 2 influence human immunodeficiency virus infection and pathogenesis?. J Infect Dis 2003, 187(May (10)):1509-1512.
3. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002, 347(November (21)):1652-1661.
4. Corey L., Langenberg A.G., Ashley R., Sekulovich R.E., Izu A.E., Douglas J.M., et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 1999, 282(July (4)):331-340.
5. Cunningham A.L., Mikloska Z. The Holy Grail: immune control of human herpes simplex virus infection and disease. Herpes 2001, 8(March (Suppl. 1)):6A-10A.
6. Koelle D.M., Corey L. Herpes simplex: insights on pathogenesis and possible vaccines. Annu Rev Med 2008, 59:381-395.
7. Peng T., Ponce-de-Leon M., Jiang H., Dubin G., Lubinski J.M., Eisenberg R.J., et al. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge. J Virol 1998, 72(January (1)):65-72.
8. Mikloska Z., Cunningham A.L. Herpes simplex virus type 1 glycoproteins gB, gC and gD are major targets for CD4 T-lymphocyte cytotoxicity in HLA-DR expressing human epidermal keratinocytes. J Gen Virol 1998, 79(February (Pt 2)):353-361.
9. Koelle D.M., Corey L., Burke R.L., Eisenberg R.J., Cohen G.H., Pichyangkura R., et al. Antigenic specificities of human CD4+ T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. J Virol 1994, 68(May (5)):2803-2810.
10. Heldwein E.E., Krummenacher C. Entry of herpesviruses into mammalian cells. Cell Mol Life Sci 2008, 65(June (11)):1653-1668.
11. Hoshino Y., Pesnicak L., Dowdell K.C., Burbelo P.D., Knipe D.M., Straus S.E., et al. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J Infect Dis 2009, 200(October (7)):1088-1095.
12. Stanberry L.R., Bernstein D.I., Burke R.L., Pachl C., Myers M.G. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis 1987, 155(May (5)):914-920.
13. Bourne N., Bravo F.J., Francotte M., Bernstein D.I., Myers M.G., Slaoui M., et al. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J Infect Dis 2003, 187(February (4)):542-549.
14. McClements W.L., Armstrong M.E., Keys R.D., Liu M.A. The prophylactic effect of immunization with DNA encoding herpes simplex virus glycoproteins on HSV-induced disease in guinea pigs. Vaccine 1997, 15(June (8)):857-860.
15. Ghiasi H., Nesburn A.B., Wechsler S.L. Vaccination with a cocktail of seven recombinantly expressed HSV-1 glycoproteins protects against ocular HSV-1 challenge more efficiently than vaccination with any individual glycoprotein. Vaccine 1996, 14(February (2)):107-112.
16. Bernstein D.I., Farley N., Bravo F.J., Earwood J., McNeal M., Fairman J., et al. The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs. Vaccine 2010, 28(May (21)):3748-3753.
17. Rux A.H., Willis S.H., Nicola A.V., Hou W., Peng C., Lou H., et al. Functional region IV of glycoprotein D from herpes simplex virus modulates glycoprotein binding to the herpesvirus entry mediator. J Virol 1998, 72(September (9)):7091-7098.
18. Willis S.H., Peng C., Ponce de Leon M., Nicola A.V., Rux A., Cohen G.G., et al. Expression and purification of secreted forms of HSV glycoproteins from baculovirus-infected insect cells. Methods in molecular, herpes simplex virus protocols 1998, 131-136. Humana Press, Inc., Totowa, NJ. S.M. Brown, A.R. MacLean (Eds.).
19. Spear P.G., Eisenberg R.J., Cohen G.H. Three classes of cell surface receptors for alphaherpesvirus entry. Virology 2000, 275(September (1)):1-8.
20. Lasaro M.O., Tatsis N., Hensley S.E., Whitbeck J.C., Lin S.W., Rux J.J., et al. Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses. Nat Med 2008, 14(February (2)):205-212.
21. Willis S.H., Rux A.H., Peng C., Whitbeck J.C., Nicola A.V., Lou H., et al. Examination of the kinetics of herpes simplex virus glycoprotein D binding to the herpesvirus entry mediator, using surface plasmon resonance. J Virol 1998, 72(July (7)):5937-5947.
22. Whitbeck J.C., Muggeridge M.I., Rux A.H., Hou W., Krummenacher C., Lou H., et al. The major neutralizing antigenic site on herpes simplex virus glycoprotein D overlaps a receptor-binding domain. J Virol 1999, 73(December (12)):9879-9890.
23. Krummenacher C., Rux A.H., Whitbeck J.C., Ponce-de-Leon M., Lou H., Baribaud I., et al. The first immunoglobulin-like domain of HveC is sufficient to bind herpes simplex virus gD with full affinity, while the third domain is involved in oligomerization of HveC. J Virol 1999, 73(October (10)):8127-8137.
24. Krummenacher C., Supekar V.M., Whitbeck J.C., Lazear E., Connolly S.A., Eisenberg R.J., et al. Structure of unliganded HSV gD reveals a mechanism for receptor-mediated activation of virus entry. EMBO J 2005, 24(December (23)):4144-4153.
25. Stiles K.M., Whitbeck J.C., Lou H., Cohen G.H., Eisenberg R.J., Krummenacher C. Herpes simplex virus glycoprotein D interferes with binding of herpesvirus entry mediator to its ligands through downregulation and direct competition. J Virol 2010, 84(November (22)):11646-11660.
26. Bernstein D.I., Cardin R.D., Bravo F.J., Strasser J.E., Farley N., Chalk C., et al. Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines. Clin Vaccine Immunol 2009, 16(May (5)):699-705.
27. Gursel I., Gursel M., Ishii K.J., Klinman D.M. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol 2001, 167(September (6)):3324-3328.
28. Dow S.W., Fradkin L.G., Liggitt D.H., Willson A.P., Heath T.D., Potter T.A. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 1999, 163(August (3)):1552-1561.
29. Zaks K., Jordan M., Guth A., Sellins K., Kedl R., Izzo A., et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 2006, 176(June (12)):7335-7345.
30. Bettahi I., Zhang X., Afifi R.E., BenMohamed L. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response. Viral Immunol 2006, 19(Summer (2)):220-236.
31. Chentoufi A.A., Zhang X., Lamberth K., Dasgupta G., Bettahi I., Nguyen A., et al. HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. J Immunol 2008, 180(January (1)):426-437.
32. Fairman J., Moore J., Lemieux M., Van Rompay K., Geng Y., Warner J., et al. Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study. Hum Vaccines 2008, 5(July (2)).
33. Lay M., Callejo B., Chang S., Hong D.K., Lewis D.B., Carroll T.D., et al. Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone((R))) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine 2009, 27(June (29)):3811-3820.
34. Hong D.K., Chang S., Botham C.M., Giffon T.D., Fairman J., Lewis D.B. Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity. J Virol 2010, 84(December (24)):12691-12702.
35. Sisk W.P., Bradley J.D., Leipold R.J., Stoltzfus A.M., Ponce de Leon M., Hilf M., et al. Highlevel expression and purification of secreted forms of herpes simplex virus type 1 glycoprotein gD synthesized by baculovirus-infected insect cells. J Virol 1994, 68(February (2)):766-775.
36. Koelle D.M., Chen H.B., Gavin M.A., Wald A., Kwok W.W., Corey L. CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells. J Immunol 2001, 166(March (6)):4049-4058.
37. Chowdary T.K., Cairns T.M., Atanasiu D., Cohen G.H., Eisenberg R.J., Heldwein E.E. Crystal structure of the conserved herpesvirus fusion regulator complex gH-gL. Nat Struct Mol Biol 2010, 17(July (7)):882-888.
38. Bourne N., Milligan G.N., Stanberry L.R., Stegall R., Pyles R.B. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. J Infect Dis 2005, 192(December (12)):2117-2123.
39. Mertz G.J. Asymptomatic shedding of herpes simplex virus 1 and 2: implications for prevention of transmission. J Infect Dis 2008, 198(October (8)):1098-1100.
40. Mertz G.J., Schmidt O., Jourden J.L., Guinan M.E., Remington M.L., Fahnlander A., et al. Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sexually transmitted diseases 1985, 12(January-March (1)):33-39.
41. Sawtell N.M., Thompson R.L., Stanberry L.R., Bernstein D.I. Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo. J Infect Dis 2001, 184(October (8)):964-971.
42. Bernstein D.I., Miller R.L., Harrison C.J. Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs. J Infect Dis 1993, 167(March (3)):731-735.
43. Braun R.P., Payne L.G., Dong L. Characterization of the IFN-gamma T-cell responses to immediate early antigens in humans with genital herpes. Virol J 2006, 3:54.